Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04278131 · ClinicalTrials.gov registry record · Phase 1
BS01 in Patients With Retinitis Pigmentosa
A Phase 1 study of Retinitis Pigmentosa, sponsored by Bionic Sight.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04278131 is a Phase 1 study of Retinitis Pigmentosa that is actively recruiting participants, run by Bionic Sight. The registered enrollment target is 20 participants, below the 261-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04278131, a Phase 1 study of Retinitis Pigmentosa, is actively recruiting participants, sponsored by Bionic Sight.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa
Conditions Studied
Interventions
- DRUG BS01
Study Locations (1)
New Jersey
- New Jersey Retina - Teaneck
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-02-06 |
| Est. Completion | 2029-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04278131
The ClinicalTrials.gov registry entry for NCT04278131 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 261-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (92% lower). The listed sponsor is Bionic Sight, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 1 intervention - of which BS01 is the first listed.
NCT04278131 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT04278131 about?
NCT04278131 is a clinical study titled "BS01 in Patients With Retinitis Pigmentosa". A Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa
What is the current status of trial NCT04278131?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2020-02-06. Estimated completion is 2029-12-30.
What conditions does trial NCT04278131 study?
This clinical trial studies the following conditions: Retinitis Pigmentosa.
What interventions are being tested in trial NCT04278131?
The interventions under investigation include: BS01 (DRUG).
Who is sponsoring clinical trial NCT04278131?
This trial is sponsored by Bionic Sight, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04278131 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinitis Pigmentosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Promising ROd-cone DYstrophy Gene therapY
RECRUITING · Phase 1
-
A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa
RECRUITING · Phase 1
-
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
RECRUITING · Phase 1
-
Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy
ACTIVE NOT RECRUITING · Phase 1
-
Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)
ACTIVE NOT RECRUITING · Phase 1
-
CNS10-NPC for the Treatment of RP
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.